Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs

Published:2021 Issue:2 Volume:11 Page:612-636
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Muddassir Mohd.¹²³⁴⁵^ORCID,Soni Kunjal⁶⁷⁸⁹^ORCID,Sangani Chetan B.⁶⁷⁸⁹,Alarifi Abdullah¹²³⁴⁵,Afzal Mohd.¹²³⁴⁵,Abduh Naaser A. Y.¹²³⁴⁵,Duan Yongtao¹⁰¹¹¹²¹³¹⁴,Bhadja Poonam¹⁵¹⁶¹⁷¹⁸¹⁹^ORCID

Affiliation:

1. Department of Chemistry

2. College of Science

3. King Saud University

4. Riyadh 11451

5. KSA

6. Shri Maneklal M. Patel Institute of Sciences and Research

7. Kadi Sarva Vishwavidyalaya University

8. Gandhinagar

9. India

10. Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases

11. Zhengzhou Children's Hospital

12. Zhengzhou University

13. Zhengzhou 450018

14. China

15. Arthropod Ecology and Biological Control Research Group

16. Ton Duc Thang University

17. Ho Chi Minh City

18. Vietnam

19. Faculty of Environment and Labour Safety

Abstract

Alteration in the pattern of epigenetic marking leads to cancer, neurological disorders, inflammatory problems etc.

Funder

China Postdoctoral Science Foundation

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/RA/D0RA07971E

Reference252 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Waste disposal—An attractive strategy for cancer therapy

3. Developments in therapy with monoclonal antibodies and related proteins

4. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

5. Nanobody-based cancer therapy of solid tumors

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel magnetic ligand-based assay for the electrochemical determination of BRD4;Talanta;2024-11

2. Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy;Bioorganic & Medicinal Chemistry;2024-10

3. BRD4-targeting PROTACs Synergize With Chemotherapeutics Against Osteosarcoma Cell Lines;Anticancer Research;2024-02-29

4. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands;Bioorganic & Medicinal Chemistry;2023-05

5. Recent Advances on Small-Molecule Bromodomain-Containing Histone Acetyltransferase Inhibitors;Journal of Medicinal Chemistry;2023-01-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3